Key facts
- Cyted Health’s last known valuation is $51.5M (Aug 2025).
- It has raised $67.9M; the latest was Later Stage VC ($43.8M) in Aug 2025.
- Notable investors include Innovate UK, MedTech Innovator, British Business Bank, BGF (Financial Services), Morningside Group — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Cyted Health
- ·The full record, as it builds
Funding rounds
No funding rounds for Cyted Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cyted Health
Developer of a digital diagnostic infrastructure platform designed to detect the early stages of cancer. The company's platform uses artificial intelligence and novel biomarkers to detect and diagnose clinical insights, enabling caregivers to improve patient outcomes through quality monitoring and analytics.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2018
- Employees
- 63
- Website
- cytedhealth.com/
- Ownership
- Privately Held (backing)
Cyted Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cyted Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cyted Health in its N-PORT filings yet. We sweep new filings monthly.